Business & price at a glance
The model estimate is 89.8% below the stored share price. This gap depends on the valuation assumptions; it is not a predicted price move. Indicative estimate. The calculated cash-flow value is shown separately because terminal assumptions, a downside equity shortfall or disagreement with other models limits its reliability. Read its sensitivity range before relying on the headline estimate.
Explore the modelsRevenue
Jun 2026 vs Jun 2025
Reported revenue: ₹162 CrNet profit
Jun 2026 vs Jun 2025
Reported net profit: ₹26 CrProfit into cash
Operating cash flow / net profit
Matched annual period: Mar 2026₹0.25 of operating cash for each ₹1 of reported profit.
Latest-quarter profit rose 116.7% year on year; profit across the last four reported quarters rose 88.4%. Read the latest quarter alongside the longer trend.
Reporting dates, coverage & sources
Annual: Mar 2026 · Quarterly: Jun 2026 · Cash flow: Mar 2026. These sections refresh independently. A recent price update does not mean the financial statements are current.
Sources: Company data source. Check the company filings linked by the source for the reporting basis and exceptional items.
What the numbers reveal
See how growth, cash and financing fit together. Open any measure for its interpretation and source.
Quarterly net margin
+5.24 pp year on year
Jun 2026 vs Jun 2025Why it matters & source
Each ₹100 of revenue produced ₹16.05 of reported net profit. Compare the change with tax and other-income movements.
Net profit ÷ revenue × 100. Change is in percentage points (pp), not percent growth.
Current: ₹26.00 Cr profit / ₹162.00 Cr revenue. Prior: ₹12.00 Cr / ₹111.00 Cr.
View source tableRevenue momentum gap
Latest quarter +45.9% · trailing year +37.9%
Eight consecutive quarters ending Jun 2026Why it matters & source
The latest quarter grew faster than the four-quarter trend. This comparison describes momentum; it does not predict the next quarter.
Latest-quarter revenue YoY growth minus revenue growth of the latest four quarters against the preceding four.
Latest quarter: ₹162.00 Cr vs ₹111.00 Cr. Four-quarter totals: ₹553.00 Cr vs ₹401.00 Cr.
View source tableThree-year cash backing
Operating cash / reported profit
Mar 2024–Mar 2026 · 3 matched yearsWhy it matters & source
For every ₹1 of reported profit, the business generated ₹0.86 of operating cash across the matched years. Working capital, taxes and non-cash items can explain a gap.
Sum of operating cash flow ÷ sum of net profit over three consecutive, matching annual periods. This is not an average of yearly ratios.
Operating cash: ₹113.00 Cr. Net profit: ₹131.00 Cr.
View source tableInterest coverage
Earnings before interest and tax / interest
Mar 2026 · annual P&LWhy it matters & source
Reported earnings before interest and tax cover the interest expense 9.2 times. Other income is included; principal repayments are not.
(Profit before tax + interest expense) ÷ interest expense.
Profit before tax: ₹90.00 Cr. Interest: ₹11.00 Cr.
View source tableBorrowings / book equity
₹39.04 borrowed per ₹100 of equity
Mar 2026 · balance sheetWhy it matters & source
This compares reported borrowings with equity capital plus reserves. It is gross borrowing, not net debt; reserves are not cash.
Borrowings ÷ (equity capital + reserves), from the same balance-sheet date.
Borrowings: ₹130.00 Cr. Equity capital: ₹10.00 Cr. Reserves: ₹323.00 Cr.
View source tableCash cycle change
209 days now · 219 days before
Mar 2025 vs Mar 2024Why it matters & source
A shorter cycle can reduce the time cash is tied up in operations. A longer supplier-payment period can also shorten it, so read the components.
Cash cycle = debtor days + inventory days − payable days. Change = current cycle − prior-year cycle.
Current: 154 + 167 − 112 days. Prior: 138 + 187 − 106 days.
View source tableWhat growth does this price require?Change the assumptions and see the earnings hurdle
Start with the stored P/E of 46.70×. If the future P/E is lower, earnings must work harder to deliver the same price return.
For a 10% annual price return over 5 years at a future P/E of 35.03×.
Defaults illustrate a 25% fall in P/E, 10% annual price return and five years. They are assumptions, not forecasts. This is EPS growth, not total-profit growth; changes in share count matter. Dividends, taxes and costs are excluded.
Formula & data basis
Required growth = (1 + annual price return) × (current P/E ÷ future P/E)1 / years − 1. Returns and growth use decimals in this formula.
Uses the stored P/E and its underlying earnings basis, which may differ from the dated financial tables. Quote record: 26 September 2026, 6:35 am +05:30.
Periods are matched within each calculation; different measures may use different reporting dates. Derived from the stored tables, not live filings. Check the source reporting basis before comparing companies. About ratio analysis.
Intrinsic value & reliability
This is an assumption-based valuation, not a price target or a probability range. The number remains available for research; the evidence does not justify a firm overvalued/undervalued label.
Earnings basis: 3 reported annual EPS period(s), ending Mar 2026. The earnings-power model assumes no growth; growth businesses may trade well above that benchmark.
What limits confidence
- The calculated cash-flow value is shown separately because terminal assumptions, a downside equity shortfall or disagreement with other models limits its reliability. Read its sensitivity range before relying on the headline estimate.
- The estimate is far from the reference price (outside 0.2×–5×). Treat this as a model/market disagreement to investigate, not an automatic mispricing signal. The estimate is not pulled toward the price.
Annual earnings: Mar 2026 · Quarter: Jun 2026 · Balance sheet: Mar 2026. The price-update date does not refresh these financial statements.
Statement source: Screener company financials. Detailed cash/debt schedules: checked 27 Sep 2026 23:16 IST. Refreshes run outside Indian market hours.
All 10 valuation methods
All ten methods are assessed below; calculations appear when the required inputs are usable. Open a row’s details to see the formula, assumptions or missing data. Reference-only results do not change the intrinsic-value estimate.
| Method | Value / share | Use in estimate | Calculation & inputs |
|---|---|---|---|
| Justified P/E from ROE | ₹365.14 | Included in estimate · 16.7% | Formula & sensitivityNormalised EPS × (1 + g) × (1 − g / ROE) ÷ (cost of equity − g). Matched opening-equity ROE 17.65%; sustainable growth 3%; assumed equity return 12% (10%–14%). The multiple comes from reinvestment economics, not the stock’s current market P/E. Model range: ₹298.75 – ₹469.47. |
| Graham benchmark | ₹526.86 | Included in estimate · 16.7% | Formula & sensitivity√(22.5 × normalised EPS × matched-year book value per share). A conservative historical benchmark, not a growth-company DCF. Model range: ₹526.86 – ₹526.86. |
| Normalised earnings power | ₹320.33 | Included in estimate · 16.7% | Formula & sensitivityMedian of 3 reported annual EPS period(s), ending Mar 2026 ÷ assumed required return. Base 12%; sensitivity 10%–14%. A no-growth earnings-power benchmark; debt is not deducted twice. Model range: ₹274.57 – ₹384.40. |
| DCF — operating reinvestment | ₹394.57 | Reference only | Formula & sensitivityForecast FCFF = normalised operating NOPAT × (1 − growth / return on invested capital). Five years at 8% growth; terminal 2%; historical return on capital 12.78%. Assumed WACC 10% (8%–12%). Subtract book debt and minority claims; add reported cash and book investments, then divide by shares. Reinvestment is explicitly forecast; this does not relabel reported CFO as free cash flow. Terminal value is 84.7% of the base enterprise/cash-flow value. More than 80% of the high-case value depends on terminal assumptions. Calculated for review with zero blend weight. Model range: ₹273.85 – ₹599.18. |
| Net assets / book equity | ₹320.94 | Reference only | Formula & sensitivityDated share capital + reserves divided by current implied shares. Accounting net assets, not a property appraisal or liquidation value; excluded from the intrinsic-value blend. Model range: ₹320.94 – ₹320.94. |
| Peer EV/EBITDA | ₹2,350.58 | Reference only | Formula & sensitivitySame-industry, same-annual-period peer median of 37 other companies: 21.7×; interquartile sensitivity. Quotes ≤14 days old; verified cash/debt/minority schedules ≤30 days old. Common equity = enterprise value − debt − minority claims + cash + book investments. A relative-market benchmark with zero weight in intrinsic value; broad industry peers still require business-model review. Model range: ₹1,638.95 – ₹3,352.58. |
| Dividend discount | Not available | Needs inputs / not applicable | See missing inputsDividend model: three positive, stable payout years with positive earnings are unavailable. Low dividends alone do not prove a stock is overvalued. |
| Earnings-yield benchmark | ₹320.33 | Reference only | Formula & sensitivityNormalised EPS ÷ assumed earnings yield (12%; range 10%–14%). Mathematically the same no-growth estimate as earnings power, so it is displayed once as a reference and has zero extra blend weight. Model range: ₹274.57 – ₹384.40. |
| ROCE / economic value added | ₹342.12 | Included in estimate · 50.0% | Formula & sensitivityOperating invested capital + discounted economic profit: (forecast ROIC − WACC) × opening invested capital. Historical ROIC 12.78% fades to WACC over five years; no terminal excess return. Assumed WACC 10% (8%–12%); capital growth capped at 5%. Apply the same debt, minority, cash and book-investment bridge to common equity. Model range: ₹326.68 – ₹358.69. |
| Peer EV/revenue | ₹1,667.09 | Reference only | Formula & sensitivitySame-industry, same-annual-period peer median of 40 other companies: 3.68×; interquartile sensitivity. Quotes ≤14 days old; verified cash/debt/minority schedules ≤30 days old. Common equity = enterprise value − debt − minority claims + cash + book investments. A relative-market benchmark with zero weight in intrinsic value; broad industry peers still require business-model review. Model range: ₹1,016.21 – ₹2,652.99. |
Equal weight per eligible model family, then equal weight within each family. Accounting, duplicate and peer-market references have zero intrinsic-value weight. The headline range covers contributing models and discount-rate sensitivity, not a confidence interval. Reference scenarios have their own ranges in the table.
Model assumptions and limitations
Growth, required returns and competitive fade are disclosed model assumptions. Cash, investments, debt and minority interests use book amounts as proxies; fair-value adjustments can materially change enterprise estimates. Reference-only methods and duplicate earnings-yield calculations have zero blend weight. Book value is an accounting reference, not a liquidation-value estimate or an automatic fair price.
How the safeguards work
A usable model provides an indicative estimate even when other inputs are missing. Older results, short histories, limited model coverage and cash-quality concerns reduce confidence instead of hiding every value. An annual earnings series whose latest period is older than 36 months is not reused; four consecutive quarters can provide a fallback when annual EPS is absent. Known earnings/share-basis conflicts and trailing losses exclude affected earnings models. Book-value problems exclude book-dependent models without removing a usable earnings-power model. Justified P/E uses matched ROE and reinvestment assumptions, never the current market P/E as its valuation multiple.
Financial businesses can use equity-earnings and eligible dividend models, with a sector-review warning. CFO is never substituted for free cash flow to equity. DCF uses verified FCFE or an explicit operating-reinvestment forecast; the latter and economic-profit valuation require matched debt, cash, investments and minority interests. Related enterprise models share one blend family. Low-payout dividends, accounting net assets, duplicate earnings yield and market peer multiples remain visible as references where appropriate. Extreme price gaps prompt a warning, not an invented price cap. An automatic overvalued/undervalued label requires three models across two families, consistent inputs, recent results and agreement across the full range.
Confidence describes evidence coverage, not a measured probability of accuracy. Even the moderate rating is an automated screen. Equity models assume a 12% required return (10%–14% sensitivity); enterprise models assume 10% WACC (8%–12%). These are disclosed scenarios, not measured company-specific costs of capital. A negative enterprise-to-equity sensitivity result indicates a claims shortfall, not a negative tradable share price. No-growth earnings power and Graham are conservative benchmarks; they do not fully capture future reinvestment or growth. Check current filings and corporate actions.
Method references: CFA Institute: cash-flow valuation · Damodaran: financial-service firms
Analysis summary
Data coverage: Price-data record updated 26 September 2026, 6:35 am +05:30. Annual results through Mar 2026; quarterly results through Jun 2026; cash flow through Mar 2026. Each section can have a different reporting period. The share price is not live.
Valuation in context
Kwality Pharmaceuticals Ltd: the indicative intrinsic value estimate is ₹373.11, with a model sensitivity range of ₹274.57–₹526.86. Confidence: Limited. Reference share price: ₹3,672.00. Assessment: Indicative estimate. This range reflects model and required-return assumptions, not forecast probability or a buy/sell recommendation. The calculated cash-flow value is shown separately because terminal assumptions, a downside equity shortfall or disagreement with other models limits its reliability. Read its sensitivity range before relying on the headline estimate. The estimate is far from the reference price (outside 0.2×–5×). Treat this as a model/market disagreement to investigate, not an automatic mispricing signal. The estimate is not pulled toward the price.
Operating performance
Revenue for Mar 2026 was ₹503.00 Cr, versus ₹370.00 Cr in Mar 2025 (35.9% year on year). Net profit for Mar 2026 was ₹67.00 Cr, versus ₹40.00 Cr in Mar 2025 (67.5% year on year). These are the latest annual periods stored on this page; check the quarterly table separately for more recent developments.
Cash generation
For the same Mar 2026 period, operating cash flow was ₹17.00 Cr against net profit of ₹67.00 Cr. Cash flow covered 0.25 times reported profit. The gap warrants checking receivables, working capital and one-off items in the cash-flow statement.
Balance-sheet check
Reported borrowings were ₹130.00 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.
How to use the valuation and peer comparisons
The Intrinsic Value panel combines the available model estimates using the displayed weights. Earnings, cash-flow, dividend and asset-based methods can give very different answers. The base required return is an assumed 12%, with 10%–14% sensitivity. Eligible dividend and FCFE models use capped terminal-growth assumptions explained in their model rows. Historical EPS growth is not a promise of future growth. Use the individual values and their spread to judge sensitivity.
The peer group follows the stored industry classification and may include different business models. Compare reporting periods, leverage and recurring earnings before interpreting a valuation gap. For banks and other financial businesses, capital adequacy and asset quality can be more informative than industrial-company cash-flow ratios.
Sources: Company data source. Check the company filings linked by the source for the reporting basis and exceptional items.
Automatically generated interpretation of the stored financial data, not a separately researched analyst opinion. Missing data is not evidence of poor performance. New filings become available here after the existing data refresh process captures them.
Business quality
Data coverage: 5/5 dimensions. Financial reporting periods vary by section.
Open a dimension to see what drives its score. Stored ratio feeds and reporting dates can differ from the matched financial-statement calculations in Connect the numbers.
Stock Health95/100 · Strong
Profitability, balance sheet strength, debt levels, profit consistency
Ownership Trends70/100 · Strong
FII/DII trends, promoter changes, shareholder count shifts
Earnings Quality75/100 · Strong
Cash flow vs reported profit, margin trends, working capital efficiency
Quarterly Momentum90/100 · Strong
Recent 4-quarter revenue and profit growth vs prior year
Peer Comparison70/100 · Strong
P/E, ROCE, ROE, and growth vs industry averages
How the quality score is calculated
Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Peer Comparison 15% · Ownership Trends 10%. Scores use stored reporting periods and are screening indicators, not investment recommendations. Missing dimensions are excluded and the remaining weights are rescaled. At least three dimensions are required for an overall score. Holding movements describe ownership shares, not proven trading flows. Broad industry groups and financial-sector accounting can limit comparability.
Share price & basic dataAll stored headline metrics · Expand table
Share Price and Basic Stock Data
Last Updated: September 26, 2026, 6:35 am
| PEG Ratio | 1.41 |
|---|
Understand these figures: how to read the P/E ratio, ROE versus earnings per share, and calculate intrinsic value.
Price & valuation history
Price and model use the left ₹ axis; P/E uses the right × axis. Stored observations, not live quotes. Historical models may use earlier methodologies.
Loading historical observations…
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Kwality Pharmaceuticals Ltd | 3,810 Cr. | 3,672 | 3,949/829 | 46.7 | 321 | 0.00 % | 23.9 % | 22.5 % | 10.0 |
| Unichem Laboratories Ltd | 3,870 Cr. | 550 | 687/278 | 31.7 | 386 | 0.00 % | 4.13 % | 3.17 % | 2.00 |
| Aarti Drugs Limited | 3,901 Cr. | 427 | 534/319 | 22.6 | 154 | 0.47 % | 11.7 % | 12.7 % | 10.0 |
| Solara Active Pharma Sciences Ltd | 3,587 Cr. | 739 | 774/422 | 840 | 346 | 0.00 % | 4.86 % | 0.13 % | 10.0 |
| Ind-Swift Laboratories Ltd | 3,516 Cr. | 404 | 420/87.0 | 54.0 | 159 | 0.00 % | 4.86 % | 4.02 % | 10.0 |
| Industry Average | 17,971.05 Cr | 1,276.48 | 56.80 | 211.60 | 0.38% | 26.16% | 16.59% | 6.06 |
Quarterly performance
Compare sales, expenses, operating profit and net profit on one chart, across the same reporting quarters.
Sales, expenses & profits
₹ croreCompare the lines together. Select a metric below to show or hide it.
Chart loads as you scroll. Values are available in the table.
Supporting financial tableAll reported figures · use a chart icon for peer comparison
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 56 | 69 | 67 | 70 | 78 | 92 | 80 | 90 | 84 | 116 | 111 | 111 | 123 | 157 | 162 |
| Expenses | 41 | 57 | 54 | 54 | 61 | 71 | 63 | 70 | 67 | 90 | 87 | 86 | 93 | 118 | 121 |
| Operating Profit | 15 | 12 | 14 | 15 | 17 | 21 | 17 | 20 | 18 | 26 | 24 | 25 | 30 | 39 | 41 |
| OPM % | 27% | 17% | 20% | 22% | 21% | 23% | 22% | 22% | 21% | 22% | 22% | 23% | 24% | 25% | 25% |
| Other Income | 0 | -15 | 0 | 0 | 1 | -7 | 0 | 0 | 1 | 1 | 0 | 1 | -0 | 1 | 1 |
| Interest | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 3 |
| Depreciation | 4 | 4 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 10 | -10 | 7 | 8 | 10 | 6 | 11 | 13 | 11 | 19 | 17 | 18 | 22 | 32 | 34 |
| Tax % | 28% | -24% | 25% | 24% | 21% | 28% | 25% | 33% | 25% | 24% | 30% | 23% | 28% | 20% | 25% |
| Net Profit | 7 | -7 | 5 | 6 | 8 | 4 | 8 | 8 | 9 | 14 | 12 | 14 | 16 | 25 | 26 |
| EPS in Rs | 6.97 | -7.09 | 5.25 | 6.03 | 7.42 | 4.34 | 8.07 | 8.18 | 8.23 | 13.97 | 11.50 | 13.61 | 15.43 | 24.37 | 24.70 |
Last Updated: September 27, 2026, 6:02 am
Annual performance
Compare sales, expenses, operating profit and net profit across financial years. Trailing figures remain in the table.
Sales, expenses & profits
₹ croreCompare the lines together. Select a metric below to show or hide it.
Chart loads as you scroll. Values are available in the table.
Earnings per share
₹ per shareHover or tap the chart for dated values.
Chart loads as you scroll. Values are available in the table.
Supporting financial tableAll reported figures · use a chart icon for peer comparison
Profit & Loss - Annual Report
Last Updated: September 27, 2026, 6:02 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 52 | 76 | 95 | 137 | 165 | 138 | 261 | 456 | 251 | 307 | 370 | 503 | 554 |
| Expenses | 56 | 49 | 70 | 86 | 125 | 149 | 124 | 231 | 284 | 190 | 241 | 290 | 385 | 419 |
| Operating Profit | 4 | 4 | 6 | 9 | 12 | 15 | 14 | 29 | 172 | 61 | 67 | 80 | 118 | 135 |
| OPM % | 6% | 7% | 8% | 9% | 8% | 9% | 10% | 11% | 38% | 24% | 22% | 22% | 24% | 24% |
| Other Income | 0 | 1 | 0 | 2 | 1 | 1 | 4 | 2 | 4 | -14 | -5 | 2 | 2 | 2 |
| Interest | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 7 | 10 | 10 | 11 | 11 |
| Depreciation | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 6 | 11 | 15 | 20 | 18 | 20 | 20 |
| Profit before tax | 2 | 2 | 3 | 6 | 8 | 11 | 11 | 22 | 162 | 26 | 31 | 54 | 90 | 106 |
| Tax % | 47% | 29% | 39% | 41% | 38% | 31% | 24% | 29% | 26% | 24% | 24% | 26% | 25% | |
| Net Profit | 1 | 1 | 2 | 3 | 5 | 8 | 8 | 15 | 120 | 19 | 24 | 40 | 67 | 81 |
| EPS in Rs | 0.95 | 1.32 | 1.89 | 3.31 | 4.51 | 7.28 | 8.12 | 14.86 | 115.70 | 18.76 | 23.11 | 38.44 | 64.91 | 78.11 |
| Dividend Payout % | 0% | 0% | 0% | 9% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth
Last Updated: September 5, 2025, 9:25 am
Balance sheet
Compare reserves and borrowings across the same financial years. Reserves are an accounting balance, not available cash.
Reserves & borrowings
₹ croreCompare the lines together. Select a metric below to show or hide it.
Chart loads as you scroll. Values are available in the table.
Supporting financial tableAll reported figures · use a chart icon for peer comparison
Balance Sheet
Last Updated: July 6, 2026, 4:00 am
| Month | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 5 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 15 | 18 | 21 | 21 | 28 | 37 | 52 | 172 | 192 | 216 | 255 | 323 |
| Borrowings | 8 | 13 | 19 | 26 | 28 | 35 | 41 | 54 | 90 | 98 | 112 | 130 |
| Other Liabilities | 10 | 17 | 27 | 41 | 40 | 53 | 65 | 106 | 71 | 74 | 72 | 132 |
| Total Liabilities | 38 | 52 | 72 | 98 | 107 | 135 | 169 | 343 | 364 | 398 | 451 | 596 |
| Fixed Assets | 11 | 11 | 16 | 19 | 28 | 42 | 56 | 91 | 120 | 138 | 144 | 154 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 12 | 14 | 0 | 0 | 17 |
| Investments | 4 | 5 | 7 | 9 | 8 | 8 | 9 | 4 | 4 | 4 | 4 | 4 |
| Other Assets | 23 | 36 | 50 | 70 | 71 | 86 | 102 | 236 | 226 | 256 | 303 | 421 |
| Total Assets | 38 | 52 | 72 | 98 | 107 | 135 | 169 | 343 | 364 | 398 | 451 | 596 |
Cash generation
Compare operating cash and free cash flow across reported periods. Negative values remain visible.
Operating & free cash flow
₹ croreCompare the lines together. Select a metric below to show or hide it.
Chart loads as you scroll. Values are available in the table.
Supporting financial tableAll reported figures · use a chart icon for peer comparison
Cash Flow
| Month | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free cash flowAll reported figures · use a chart icon for peer comparison
Free Cash Flow
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.00 | -5.00 | -3.00 | -6.00 | 1.00 | -12.00 | 3.00 | 4.00 | -4.00 | 18.00 | 28.00 | -29.00 |
This table and the chart use the Free Cash Flow row from the same stored cash-flow statement. Free cash flow generally measures operating cash flow after capital expenditure; check the source definition and reporting basis. It is not operating profit minus borrowings.
Financial & business efficiency
Compare collection, inventory, payment and working-capital cycles together in days. Returns on capital and equity follow in a separate percentage chart.
Working capital
DaysCompare the lines together. Select a metric below to show or hide it.
Chart loads as you scroll. Values are available in the table.
Returns on capital & equity
%Hover or tap the chart for dated values.
Chart loads as you scroll. Values are available in the table.
Supporting financial tableAll reported figures · use a chart icon for peer comparison
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 41 | 63 | 95 | 87 | 99 | 86 | 80 | 53 | 57 | 107 | 138 | 154 |
| Inventory Days | 58 | 61 | 54 | 72 | 54 | 34 | 94 | 38 | 97 | 310 | 187 | 167 |
| Days Payable | 58 | 40 | 61 | 67 | 79 | 52 | 96 | 58 | 63 | 117 | 106 | 112 |
| Cash Conversion Cycle | 41 | 85 | 89 | 92 | 74 | 68 | 78 | 33 | 91 | 300 | 219 | 209 |
| Working Capital Days | 60 | 35 | 41 | 21 | 19 | 21 | 43 | 25 | 62 | 120 | 103 | 100 |
| ROCE % | 12% | 11% | 15% | 19% | 19% | 21% | 18% | 26% | 97% | 18% | 16% | 18% |
Ownership trends
Compare ownership groups across the same reporting dates. Shareholder counts appear separately below.
Shareholding comparison
%Compare the lines together. Select a metric below to show or hide it.
Chart loads as you scroll. Values are available in the table.
Shareholder count
ShareholdersHover or tap the chart for dated values.
Chart loads as you scroll. Values are available in the table.
Supporting financial tableAll reported figures · use a chart icon for peer comparison
This stock is not held by any mutual fund.
Additional ratios
Related measures share a chart and a common unit. Use the dated figures below to examine any change.
Profitability ratios
%Compare the lines together. Select a metric below to show or hide it.
Chart loads as you scroll. Values are available in the table.
Liquidity ratios
Multiple (×)Compare the lines together. Select a metric below to show or hide it.
Chart loads as you scroll. Values are available in the table.
Interest coverage
Multiple (×)Compare the lines together. Select a metric below to show or hide it.
Chart loads as you scroll. Values are available in the table.
Valuation multiples
Multiple (×)Compare the lines together. Select a metric below to show or hide it.
Chart loads as you scroll. Values are available in the table.
Supporting financial tableAll reported figures · use a chart icon for peer comparison
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 38.36 | 22.76 | 18.16 | 115.64 | 14.60 |
| Diluted EPS (Rs.) | 38.36 | 22.76 | 18.16 | 115.64 | 14.60 |
| Cash EPS (Rs.) | 55.99 | 41.61 | 33.00 | 125.89 | 20.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 253.70 | 213.74 | 191.08 | 172.50 | 56.91 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 254.47 | 214.51 | 191.85 | 173.27 | 57.68 |
| Revenue From Operations / Share (Rs.) | 356.77 | 296.03 | 241.93 | 439.64 | 252.51 |
| PBDIT / Share (Rs.) | 79.32 | 65.67 | 60.79 | 168.82 | 29.33 |
| PBIT / Share (Rs.) | 61.70 | 46.82 | 46.38 | 158.52 | 23.07 |
| PBT / Share (Rs.) | 52.18 | 29.97 | 24.65 | 155.71 | 20.50 |
| Net Profit / Share (Rs.) | 38.36 | 22.76 | 18.58 | 115.59 | 14.35 |
| NP After MI And SOA / Share (Rs.) | 38.40 | 22.93 | 18.67 | 115.64 | 14.60 |
| PBDIT Margin (%) | 22.23 | 22.18 | 25.12 | 38.39 | 11.61 |
| PBIT Margin (%) | 17.29 | 15.81 | 19.16 | 36.05 | 9.13 |
| PBT Margin (%) | 14.62 | 10.12 | 10.18 | 35.41 | 8.11 |
| Net Profit Margin (%) | 10.75 | 7.68 | 7.68 | 26.29 | 5.68 |
| NP After MI And SOA Margin (%) | 10.76 | 7.74 | 7.71 | 26.30 | 5.78 |
| Return on Networth / Equity (%) | 15.13 | 10.65 | 9.69 | 66.53 | 25.09 |
| Return on Capital Employeed (%) | 23.04 | 20.04 | 21.13 | 78.21 | 27.21 |
| Return On Assets (%) | 8.90 | 6.03 | 5.47 | 35.23 | 9.10 |
| Long Term Debt / Equity (X) | 0.05 | 0.08 | 0.13 | 0.11 | 0.30 |
| Total Debt / Equity (X) | 0.42 | 0.43 | 0.45 | 0.24 | 0.57 |
| Asset Turnover Ratio (%) | 0.87 | 0.82 | 0.72 | 1.79 | 1.73 |
| Current Ratio (X) | 1.67 | 1.60 | 1.65 | 1.75 | 1.35 |
| Quick Ratio (X) | 1.18 | 1.08 | 0.95 | 1.34 | 1.13 |
| Inventory Turnover Ratio (X) | 4.57 | 1.87 | 1.62 | 5.64 | 8.31 |
| Interest Coverage Ratio (X) | 8.33 | 6.56 | 10.48 | 60.05 | 11.39 |
| Interest Coverage Ratio (Post Tax) (X) | 5.03 | 3.96 | 6.95 | 42.11 | 6.57 |
| Enterprise Value (Cr.) | 997.78 | 515.35 | 400.57 | 630.81 | 85.72 |
| EV / Net Operating Revenue (X) | 2.70 | 1.68 | 1.60 | 1.38 | 0.32 |
| EV / EBITDA (X) | 12.12 | 7.56 | 6.35 | 3.60 | 2.82 |
| MarketCap / Net Operating Revenue (X) | 2.44 | 1.38 | 1.27 | 1.32 | 0.22 |
| Price / BV (X) | 3.43 | 1.90 | 1.60 | 3.34 | 0.96 |
| Price / Net Operating Revenue (X) | 2.44 | 1.38 | 1.27 | 1.32 | 0.22 |
| EarningsYield | 0.04 | 0.05 | 0.06 | 0.19 | 0.26 |
Frequently asked questions
What is the intrinsic value of Kwality Pharmaceuticals Ltd and is it undervalued?
Kwality Pharmaceuticals Ltd: the indicative intrinsic value estimate is ₹373.11, with a model sensitivity range of ₹274.57–₹526.86. Confidence: Limited. Reference share price: ₹3,672.00. Assessment: Indicative estimate. This range reflects model and required-return assumptions, not forecast probability or a buy/sell recommendation. The calculated cash-flow value is shown separately because terminal assumptions, a downside equity shortfall or disagreement with other models limits its reliability. Read its sensitivity range before relying on the headline estimate. The estimate is far from the reference price (outside 0.2×–5×). Treat this as a model/market disagreement to investigate, not an automatic mispricing signal. The estimate is not pulled toward the price. The Intrinsic value & reliability section explains eligible models, excluded methods and the review rules. A low P/E or a large price gap alone does not establish mispricing.
What share price and 52-week range are shown for Kwality Pharmaceuticals Ltd?
The stored share price is ₹3,672.00. Price-data record updated: 26 September 2026, 6:35 am +05:30. This is not a live quote. The stored 52-week high / low is 3,949/829; this is a rolling range, not a financial-year range.
How have Kwality Pharmaceuticals Ltd's revenue and profit changed?
Revenue for Mar 2026 was ₹503.00 Cr, versus ₹370.00 Cr in Mar 2025 (35.9% year on year). Net profit for Mar 2026 was ₹67.00 Cr, versus ₹40.00 Cr in Mar 2025 (67.5% year on year). These are the latest annual periods stored on this page; check the quarterly table separately for more recent developments.
Does Kwality Pharmaceuticals Ltd's profit convert into cash?
For the same Mar 2026 period, operating cash flow was ₹17.00 Cr against net profit of ₹67.00 Cr. Cash flow covered 0.25 times reported profit. The gap warrants checking receivables, working capital and one-off items in the cash-flow statement.
What should I check in Kwality Pharmaceuticals Ltd's balance sheet?
Reported borrowings were ₹130.00 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.
How should I compare Kwality Pharmaceuticals Ltd's P/E with other stocks?
The stored P/E is 46.70. Compare companies with similar business models, growth, leverage and accounting periods. The industry group on this page is broad, and its average can be affected by outliers. A lower P/E alone does not establish undervaluation.
What could change Kwality Pharmaceuticals Ltd's intrinsic value estimate?
Changes in sustainable earnings, cash generation, capital needs, debt and share count can change the estimate. The displayed model uses a 12% cost of equity and 4% terminal growth assumption where applicable. Higher discount rates or weaker growth generally reduce discounted values. Compare the individual model values and weights, and verify fresh filings before relying on the result.